Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
One key issue remains unresolved, and it could be a significant one.
The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.